Guelfi 1999.

Methods	Twelve‐week randomised, double‐blind, multicentre study
Participants	Outpatients (general practice) fulfilling DSM‐III‐R criteria for major depressive episode, with a score of at least 25 on the Montgomery and Asberg Scale for Depression (MADRS) and a Mini Mental State Examination (MMSE) of at least 24. Age: over 65 years Exclusion criteria: not stated
Interventions	Fluoxetine: 122 participants Tianeptine: 115 participants Fluoxetine dose: 20 mg/day Tianeptine dose range: 20‐37.5 mg/day
Outcomes	Primary outcome: change in the total score on the MADRS Secondary outcomes: total number of responders at endpoint, total number of remissions at endpoint, mean variation on the Geriatric Depression Scale (GDS)
Notes	Response: decrease of at least 50% in the MADRS total score Remission: total score less than 10 on the MADRS Funding: by industry
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "deux groupes de traitment ont été constitués par tirage au sorte", randomised, no further information
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Double blind, no further information
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double blind, no further information
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Double blind, no further information
Incomplete outcome data (attrition bias) All outcomes	Low risk	Mean endpoint scores reported with denominators. Dropouts reported with reasons
Selective reporting (reporting bias)	Low risk	Side effects reported
Other bias	High risk	Author's affiliation was Eli Lilly and this company produces fluoxetine